Patients who achieved at least a 50% reduction in Psoriasis Area and Severity Index (PASI50) response at week 13 were then randomly assigned 1:1 to either be switched between Humira and Hadlima or ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial ...

INCHEON, Korea & JERSEY CITY, N.J. - Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) have announced the U.S. Food and Drug Administration’s (FDA) approval of HADLIMA™ (adalimumab-bwwd ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...

5 As a company dedicated to making medicines more accessible, HADLIMA, now designated as fully interchangeable with the reference product, has a greater potential to bring savings for patients.

INCHEON, Korea & JERSEY CITY, N.J. - Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) have announced the U.S. Food and Drug Administration’s (FDA) approval of HADLIMA™ (adalimumab-bwwd) as an ...

Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for appropriate patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis ...